
Molecular Therapy as a Future Strategy in Endometrial Cancer
Author(s) -
Duangmani Thanapprapasr,
Kamolrat Thanapprapasr
Publication year - 2013
Publication title -
asian pacific journal of cancer prevention
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.512
H-Index - 75
eISSN - 2476-762X
pISSN - 1513-7368
DOI - 10.7314/apjcp.2013.14.6.3419
Subject(s) - endometrial cancer , medicine , oncology , tyrosine kinase inhibitor , adjuvant , cancer , adjuvant therapy , chemotherapy , incidence (geometry) , gynecologic cancer , pi3k/akt/mtor pathway , targeted therapy , tamoxifen , gynecology , ovarian cancer , breast cancer , signal transduction , biochemistry , physics , chemistry , optics
Of all gynecologic cancers, endometrial cancer is the most common cancer in the US and Europe. In addition, it is presently the second most common gynecologic cancer in the world. As a result of increasing menopausal, obese and tamoxifen use women, the incidence of the cancer seems to be on the increase. Surgery is the major treatment, whereas postoperative radiation therapy in high-intermediate risk patients many prevent locoregional recurrence. Adjuvant chemotherapy can improve progression free survival in advanced or recurrent cancers. Molecular targeted therapies are now a focus of attention including anti-vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR) inhibitor and tyrosine kinase inhibitor (TKI). They may provide useful future strategies for control of endometrial malignancies in developing countries and across the world.